Ablation to improve wellbeing and survival in people aged 80 and older with atrial fibrillation
Official title: Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly (WISER-AF)
Run by Beijing Anzhen Hospital · NCT07403760 · Data updated 2026-11-12
This will see if catheter ablation, compared with a sham procedure, improves quality of life over six months for people aged 80 and older with symptomatic atrial fibrillation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 80 Years and up |
| Sex | All |
| Enrollment | 136 (estimated) |
| Sponsor | Beijing Anzhen Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | July 1, 2026 |
| Main results expected | November 30, 2028 |
| Study ends | December 30, 2028 |
| Registry record updated | July 6, 2026 |
| Trial ID | NCT07403760 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 80 or older with documented paroxysmal or persistent symptomatic AF who can give informed consent and meet procedural safety criteria.
✕Probably not a fit
Patients with long-standing persistent AF, advanced heart failure (NYHA IV), significant organ failure, left atrial thrombus, prior AF ablation, or other listed exclusion criteria are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
WISER-AF is a multicenter, double-blind, sham-controlled randomized trial enrolling 182 symptomatic patients aged 80 or older in Beijing, China. Participants are randomized 1:1 to pulsed field catheter ablation or a sham procedure, with blinding supported by eye masks, headphones, and phrenic nerve stimulation in the sham arm. The primary outcome is change in the SF-36 total score from baseline to six months, and secondary outcomes include AFEQT, Clinical Frailty Scale, LVEF, NT-proBNP, 6-minute walk distance, and cardiovascular events. The design focuses on patient-reported quality of life and functional measures rather than only rhythm outcomes.
Why it matters
Potential benefit: If successful, ablation could meaningfully improve symptoms and overall quality of life for very elderly patients with symptomatic atrial fibrillation.
How similar studies have gone: Previous ablation trials in broader AF populations have shown symptom and quality-of-life benefits, but sham-controlled data specifically in people aged 80 and older are limited, making this approach relatively novel for the very elderly.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 80 years. 2. Documented paroxysmal or persistent atrial fibrillation by ECG or Holter within 6 months prior to enrollment. 3. Symptomatic AF (including palpitations, chest tightness, fatigue, dizziness, blackouts, dyspnea). 4. Voluntary participation and signed informed consent. Exclusion Criteria: 1. NYHA Class IV heart failure. 2. Acute myocardial infarction, cardiac surgery, or PCI within the past 1 year. 3. Long-standing persistent AF (duration \> 1 year). 4. Left atrial anteroposterior diameter \> 6 cm. 5. History of prior AF ablation. 6. AF secondary to reversible causes (e.g., post-surgery, infection, hyperthyroidism). 7. Severe mitral stenosis. 8. Moderate to severe hepatic failure (Child-Pugh B-C). 9. Renal failure stage 4-5 (eGFR \<30 ml/min/1.73m2) or continuous dialysis. 10. Inability to cooperate due to dementia or severe mental disorder. 11. Presence of left atrial thrombus. 12. Prior Left Atrial Appendage Occlusion (LAAO). 13. Contraindication to anticoagulation. 14. Life expectancy \< 1 year.
Where it's running
-
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
Beijing, China Recruiting
Study contacts
- Principal investigator: Changsheng Ma, Prof. — Beijing Anzhen Hospital
- Study coordinator: Liu He, PhD
- Email: theliu@139.com
- Phone: +86 13810720787
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pulsed Field vs Cryoballoon for Pulmonary Vein Isolation in Atrial Fibrillation
This trial tests whether pulsed field ablation can shorten the procedure for first-time PVI in AF patients compared with cryoballoon ablation, while keeping safety and effectiveness similar.
-
Pulsed Field Ablation vs Cryoablation for Atrial Fibrillation Under Deep Sedation
This trial tests whether pulsed field ablation (PFA) done under deep sedation works as well as cryoballoon ablation for treating atrial fibrillation, aiming to avoid general anesthesia.
-
Bachmann’s Bundle Pacing vs Right Atrial Appendage Pacing for AF
This study tests two common atrial pacing methods to see which one is safer over 12 months for people getting a new pacemaker, ICD, or CRT device.
-
AI-powered ECG to help diagnose and predict outcomes in heart disease
Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.
-
Pace-and-ablate strategy in atrial fibrillation: who benefits and long-term outcomes
This study looks at adults with atrial fibrillation who underwent AV node ablation with permanent pacing to see who develops pacing-induced problems and how they do long-term.
-
AI-based cardiac analysis using 12-lead and 1-lead ECG
A clinician-facing pilot test to see if SmartECG-EF helps evaluate heart function using both 12-lead and single-lead ECGs in adults with heart conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.